EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Burns - Pipeline Review, H1 2017

  • ID: 4115129
  • Report
  • March 2017
  • 90 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AlgiPharma AS
  • Biogenomics Ltd
  • Destiny Pharma Ltd
  • Lakewood-Amedex Inc
  • Mallinckrodt Plc
  • Phosphagenics Ltd
  • MORE
Burns - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Burns - Pipeline Review, H1 2017, provides an overview of the Burns (Dermatology) pipeline landscape.

A burn is damage to body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Burns - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Burns (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burns (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 4, 2, 11, 5 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Burns (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Burns (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Burns (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Burns (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Burns (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Burns (Dermatology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Burns (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Burns (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AlgiPharma AS
  • Biogenomics Ltd
  • Destiny Pharma Ltd
  • Lakewood-Amedex Inc
  • Mallinckrodt Plc
  • Phosphagenics Ltd
  • MORE
Introduction

Burns - Overview

Burns - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Burns - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Burns - Companies Involved in Therapeutics Development

AlgiPharma AS

Alliance Pharma Plc

Amarantus Bioscience Holdings Inc

American Gene Technologies International Inc

Biogenomics Ltd

CytoTools AG

Destiny Pharma Ltd

GangaGen Inc

Lakewood-Amedex Inc

Madam Therapeutics BV

Mallinckrodt Plc

MediWound Ltd

Mitochon Pharmaceuticals Inc

Phosphagenics Ltd

Se-cure Pharmaceuticals Ltd

USV Pvt Ltd

Burns - Drug Profiles

(cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

A-3APO - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AG-110 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

albumin (recombinant) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALLO-ASC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AyuV-25 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologics for Multi Drug Resistant Bacterial Infections, Dermatology and Cystic Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bromelains - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Dermatology and Immunology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epidermal growth factor biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Burns - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMSP-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neu-2000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nu-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligomer G for Burn Wounds - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-128 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-148 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEP-04 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

silver sulfadiazine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Burns - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium hypochlorite - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vanadis-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XF-70 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Burns - Dormant Projects

Burns - Discontinued Products

Burns - Product Development Milestones

Featured News & Press Releases

Mar 03, 2017: Cost Analysis Demonstrating Significant Health Care Savings Utilizing NexoBrid in Burn Management Published in BioMed Research International

Feb 09, 2017: Favorable Results from NexoBrid Phase 2 Pharmacokinetic Clinical Study Support Treatment of Severe Burns Covering up to 30% of Total Body Surface Area

Feb 06, 2017: MediWound Initiates Second Stage of European Pediatric Phase 3 Study of NexoBrid Expanding Treatment of Severe Burns to Children Age One to Four

Aug 24, 2016: MediWound's NexoBrid to be Featured at International Society for Burn Injuries

Aug 08, 2016: Amarantus Announces Publication of Human Clinical Data for Engineered Skin Substitute in the Treatment of Life-Threatening Pediatric Severe Burns

Jun 07, 2016: MediWound’s NexoBrid Receives Reimbursement in Italy

May 19, 2016: MediWound’s NexoBrid Highlighted in “Best Oral Presentation” at the British Burn Association 49th Annual Conference and Scientific Meeting

May 02, 2016: MediWound’s NexoBrid to be Highlighted in Presentations at the American Burn Association 48th Annual Meeting

Feb 29, 2016: MediWound Expands NexoBrid to India, Bangladesh and Sri Lanka Through Distribution Agreement With Learning Organized

Feb 22, 2016: Amarantus and Lonza Walkersville, Inc. Provide Update on cGMP Manufacturing Readiness for the Engineered Skin Substitute (ESS) Program

Feb 03, 2016: Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)

Jan 11, 2016: MediWound's NexoBrid Highlighted in Presentations at the 4th International Conference on Healthcare System Preparedness and Response to Emergencies and Disasters

Nov 02, 2015: MediWound Provides Humanitarian Aid for a Mass Casualty Event in Romania

Oct 31, 2015: Anterogen: Phase II IND Approval for "ALLO-ASC-BI"

Oct 26, 2015: Amarantus Appoints Curtis Scribner, MD MBA as Sr. Vice President of Regulatory Affairs

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Burns, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Burns - Pipeline by AlgiPharma AS, H1

Burns - Pipeline by Alliance Pharma Plc, H1

Burns - Pipeline by Amarantus Bioscience Holdings Inc, H1

Burns - Pipeline by American Gene Technologies International Inc, H1

Burns - Pipeline by Biogenomics Ltd, H1

Burns - Pipeline by CytoTools AG, H1

Burns - Pipeline by Destiny Pharma Ltd, H1

Burns - Pipeline by GangaGen Inc, H1

Burns - Pipeline by Lakewood-Amedex Inc, H1

Burns - Pipeline by Madam Therapeutics BV, H1

Burns - Pipeline by Mallinckrodt Plc, H1

Burns - Pipeline by MediWound Ltd, H1

Burns - Pipeline by Mitochon Pharmaceuticals Inc, H1

Burns - Pipeline by Phosphagenics Ltd, H1

Burns - Pipeline by Se-cure Pharmaceuticals Ltd, H1

Burns - Pipeline by USV Pvt Ltd, H1

Burns - Dormant Projects, H1

Burns - Dormant Projects, H1 2017 (Contd..1), H1

Burns - Discontinued Products, H1

List of Figures:

Number of Products under Development for Burns, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Top 10 Molecule Types, H1

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 4
  • AlgiPharma AS
  • Alliance Pharma Plc
  • Amarantus Bioscience Holdings Inc
  • American Gene Technologies International Inc
  • Biogenomics Ltd
  • CytoTools AG
  • Destiny Pharma Ltd
  • GangaGen Inc
  • Lakewood-Amedex Inc
  • Madam Therapeutics BV
  • Mallinckrodt Plc
  • MediWound Ltd
  • Mitochon Pharmaceuticals Inc
  • Phosphagenics Ltd
  • Se-cure Pharmaceuticals Ltd
  • USV Pvt Ltd
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll